/
ALVO
$3.72+$0.04 (+1.09%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.2B
338M shares
52-week range
$2.94 – $9.94
11% from low
Exchange
NASDAQ
CS
Borrow rate
3.43%
Moderate
Price (6 mo)
Loading chart…
Change$-7.47
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $31.9M | $66.6M | $36.8M | $83.0M | $91.4M | $489.7M | $586.3M |
| Cost of revenue | $0 | $0 | $0 | $64.1M | $160.9M | $185.3M | $235.6M |
| Gross profit | $31.9M | $66.6M | $36.8M | $18.9M | −$69.4M | $304.4M | $350.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 22.8% | -75.9% | 62.2% | 59.8% |
| R&D | $95.6M | $148.1M | $191.0M | $180.6M | $210.8M | $171.3M | $184.2M |
| Operating income | −$61.4M | −$137.5M | −$235.5M | −$346.4M | −$354.9M | $69.6M | $78.2M |
| EBITDA | −$99.0M | −$177.9M | −$18.0M | −$439.8M | −$493.7M | −$32.3M | $323.4M |
| Net income | −$209.9M | −$170.0M | −$101.5M | −$513.6M | −$551.7M | −$231.9M | $27.9M |
| Net margin | -657.5% | -255.3% | -276.0% | -618.6% | -603.4% | -47.3% | 4.8% |
| EPS (diluted) | -0.86 | -5.44 | -3.25 | -2.60 | -2.43 | -0.87 | 0.10 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $663M | $0.08 | $0.04–$0.13 | 2 |
| 2027 | $805M | $0.24 | $0.14–$0.34 | 3 |
| 2028 | $981M | $0.52 | $0.18–$1.06 | 3 |
| 2029 | $1.2B | $1.08 | $1.01–$1.20 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Alvotech Ordinary Shares
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
www.alvotech.com- Employees
- 1,460
- IPO / List date
- Jun 16, 2022
Held by traders on TradeandTell
No one on the platform currently holds ALVO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ALVO as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALVO yet.
